{"organizations": [], "uuid": "e649de8e4258699d97316ee955b8eb86f3b316f2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-edwards-lifesciences-reports-qtrly/brief-edwards-lifesciences-reports-qtrly-adj-eps-of-0-94-idUSB8N19C04Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Edwards Lifesciences Reports Qtrly Adj EPS of $0.94", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-02-02T05:38:00.000+02:00", "replies_count": 0, "uuid": "e649de8e4258699d97316ee955b8eb86f3b316f2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-edwards-lifesciences-reports-qtrly/brief-edwards-lifesciences-reports-qtrly-adj-eps-of-0-94-idUSB8N19C04Z", "ord_in_thread": 0, "title": "BRIEF-Edwards Lifesciences Reports Qtrly Adj EPS of $0.94", "locations": [], "entities": {"persons": [{"name": "edwards", "sentiment": "none"}], "locations": [{"name": "edwards lifesciences", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "edwards lifesciences corp", "sentiment": "negative"}, {"name": "edwards lifesciences", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Edwards Lifesciences Corp:\n* EDWARDS LIFESCIENCES QTRLY EARNINGS PER SHARE $0.17; QTRLY ADJUSTED EARNINGS PER SHARE $0.94\n* EDWARDS LIFESCIENCES QTRLY TRANSCATHETER HEART VALVE THERAPY SALES $519.3 MILLION, UP 20.2 PERCENT\n* EDWARDS LIFESCIENCES QTRLY NET SALES $888.5 MILLION, UP 15.7 PERCENT; QTRLY ADJUSTED SALES $909.4 MILLION, UP 15.9 PERCENT\n* EDWARDS LIFESCIENCES - U.S. TAX REFORM LED TO NET $223.5 MILLION TAX EXPENSE RELATED PRIMARILY TO DEEMED REPATRIATION OF UNREMITTED FOREIGN EARNINGS\n* EDWARDS LIFESCIENCES SEES Q1 TOTAL SALES $900 MILLION - $950 MILLION; SEES Q1 ADJUSTED EARNINGS PER SHARE $1.04 - $1.14\n* EDWARDS LIFESCIENCES SEES 2018 ADJUSTED EARNINGS PER SHARE $4.43 - $4.63\n* EDWARDS LIFESCIENCES SEES 2018 SALES TO BE AT HIGHER END OF $3.5 BILLION TO $3.9 BILLION RANGE\n* Q4 EARNINGS PER SHARE VIEW $0.91, REVENUE VIEW $867.1 MILLION -- THOMSON REUTERS I/B/E/S\n* FY2018 EARNINGS PER SHARE VIEW $4.26, REVENUE VIEW $3.74 BILLION -- THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $1.03, REVENUE VIEW $901.0 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T05:38:00.000+02:00", "crawled": "2018-02-02T12:55:15.003+02:00", "highlightTitle": ""}